224 related articles for article (PubMed ID: 25658984)
1. Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.
Chalmers ZR; Ali SM; Ohgami RS; Campregher PV; Frampton GM; Yelensky R; Elvin JA; Palma NA; Erlich R; Vergilio JA; Chmielecki J; Ross JS; Stephens PJ; Hermann R; Miller VA; Miles CR
Blood Cancer J; 2015 Feb; 5(2):e278. PubMed ID: 25658984
[No Abstract] [Full Text] [Related]
2. Imatinib-responsive hypereosinophilic syndrome.
Robyn J
Leuk Res; 2006 Aug; 30(8):915-6. PubMed ID: 16530830
[No Abstract] [Full Text] [Related]
3. The results of imatinib therapy for patients with primary eosinophilic disorders.
Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
[No Abstract] [Full Text] [Related]
4. A novel FOXP1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia.
Sugimoto Y; Sada A; Shimokariya Y; Monma F; Ohishi K; Masuya M; Nobori T; Matsui T; Katayama N
Cancer Genet; 2015 Oct; 208(10):508-12. PubMed ID: 26319757
[TBL] [Abstract][Full Text] [Related]
5. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.
Miyazawa K; Kakazu N; Ohyashiki K
Int J Hematol; 2007 Jan; 85(1):5-10. PubMed ID: 17261495
[TBL] [Abstract][Full Text] [Related]
7. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
8. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
Ng HJ; Tan DC; Yiu RC; How GF
Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.
Müller AM; Martens UM; Hofmann SC; Bruckner-Tuderman L; Mertelsmann R; Lübbert M
Ann Hematol; 2006 Jan; 85(1):1-16. PubMed ID: 16136348
[TBL] [Abstract][Full Text] [Related]
10. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
Pitini V; Sturniolo G; Cavallari V; Arrigo C
Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
[No Abstract] [Full Text] [Related]
11. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
Pardanani A; Tefferi A
Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
[TBL] [Abstract][Full Text] [Related]
12. Detection of FIP1L1-PDGFRA fusion by FISH.
Ma ES; Wong KF; Wong CL; Siu LL
Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
[No Abstract] [Full Text] [Related]
13. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
[TBL] [Abstract][Full Text] [Related]
14. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
15. [FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review].
Qu SQ; Wang Y; Sun XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):159-61. PubMed ID: 23611226
[No Abstract] [Full Text] [Related]
16. FIP1L1-PDGFRα-positive hypereosinophilic syndrome in childhood: a case report and review of literature.
Farruggia P; Giugliano E; Russo D; Trizzino A; Lorenzatti R; Santoro A; D'Angelo P
J Pediatr Hematol Oncol; 2014 Jan; 36(1):e28-30. PubMed ID: 23337549
[TBL] [Abstract][Full Text] [Related]
17. [Identification of clonal proliferation of T cell and FIP1L1-PDGFRalpha fusion gene in hypereosinophilic syndrome associated with lymphomatoid papulosis which showed rapid and complete response to the treatment with imatinib].
Fujimi A; Kanisawa Y; Kikuchi S; Okuda T; Sato Y; Doi T; Ohta H; Umeda I; Nobuoka A
Nihon Naika Gakkai Zasshi; 2007 Dec; 96(12):2794-7. PubMed ID: 18203417
[No Abstract] [Full Text] [Related]
18. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB
Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602
[TBL] [Abstract][Full Text] [Related]
19. Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Arai A; Yan W; Wakabayashi S; Hayashi S; Inazawa J; Miura O
Int J Hematol; 2007 Oct; 86(3):233-7. PubMed ID: 17988989
[TBL] [Abstract][Full Text] [Related]
20. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.
Pardanani A; Ketterling RP; Li CY; Patnaik MM; Wolanskyj AP; Elliott MA; Camoriano JK; Butterfield JH; Dewald GW; Tefferi A
Leuk Res; 2006 Aug; 30(8):965-70. PubMed ID: 16406016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]